Here, we provide direct evidence that using recombinant proteins expressed in eukaryotic cells as antigen is a practical way to generate monoclonal antibodies (mAbs) against heavily glycosylated proteins. Heavily glycosylated proteins are typically difficult targets for mAb generation, being limited by unsatisfactory affinity and low specificity. Using the heavily glycosylated CD45 protein as an example, we demonstrate the entire process of expressing the protein in eukaryotic cells and using it as an antigen to generate CD45-targeting mAbs in mice. The mAbs generated showed robust affinity and specificity, which are crucial factors for differentiate circulating tumor cells from white blood cells in human breast cancer patient samples. Only 1 cell fusion and 2 cyclic sub-cloning steps were necessary before mAbs with satisfactory performance were obtained.
Introduction
Purchasing commercial mAbs is commonly done in biological laboratories to avoid the process of preparing mAbs, which is considered time-and labor-intensive [1, 2] . However, the antigen used to prepare commercial mAbs is, in most cases, not the same protein used in the customers' studies. Therefore, fluctuations in specificity between commercial mAbs and the targeted protein are inevitable [2, 3] . Moreover, economic considerations have prompted most commercial mAb providers to employ prokaryotic proteins, or peptides, instead of eukaryotically expressed proteins as the antigen. The lack of post-translational modification (for instance, glycosylation) can compromise the consistency and repeatability of studies involving glycosylated proteins [4] . To avoid these flaws of commercial mAbs, generating mAbs in one's own laboratory may be considered as a feasible alternative, especially while a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 performing studies on post-translationally modified proteins. For example, immunofluorescent labeling of the common leukocyte antigen, CD45, has become the most commonly used method to differentiate leukocytes from circulating tumor cells (CTCs) [5] [6] [7] . However, the CD45 expressed on the surface of leukocytes from patients is post-translationally modified heavily with N-and O-linked glycosylation [8] . Possible mismatches between native CD45 and commercial antibodies may markedly lower the reliability of CTC-enumeration results, which is a key issue for CTC-related clinical practices.
In this study, we demonstrated the generation of a mAb recognizing the heavily glycosylated human CD45 protein and its application oappn identifying CTCs. Instead of utilizing a prokaryotic protein or peptide, we used the eukaryotic protein as the antigen. Antibody preparation, including mouse immunization, hybridoma screening, and mAb characterization was completed in 3 months, as only 1 time hybridoma fusion and 2 cyclic sub-cloning steps were performed to acquire the anti-CD45 mAb, which showed greater affinity and consistency than commercial mAbs. This study provides direct evidence that using eukaryotic proteins to generate mAbs could become a practical solution for biological laboratories encountering affinity and specificity issues with commercial mAbs. The efforts of plasmid construction and eukaryotic protein preparation paid off in terms of less time consumption and enhanced binding affinity.
Methods and materials

Materials
A mouse anti-his tag mAb (B1169), a commercial Alexa647-conjugated anti-CD45 mAb (BDLS0479), an Alexa647 mouse IgG1 isotype control (BDLS0031), rProtein G Beads (BDTL 0003-1) and a mouse IgG control (mIgG, BF01006) were obtained from Beijing Biodragon Immunotechnologies Co., Ltd. A horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (M21001S) was purchased from Abmart Shanghai Co., Ltd. Complete Freund's adjuvant (F5881), incomplete Freund's adjuvant (F5506), PEG 1500 (807489) were purchased from Sigma-Aldrich (USA). Fetal bovine serum (FBS; 10099-141), Phosphate-buffered saline (PBS), Roswell Park Memorial Institute (RPMI) 1640 medium (SH30809.01B) and Dulbecco's modified Eagle's medium (DMEM; SH30243.01B) were obtained from Thermo Scientific, USA.
To express the recombinant human CD45-his (rhCD45-his) protein, human embryonic kidney HEK-293T cells were cultured in DMEM supplemented with 10% FBS, and 50 μg/mL penicillin and streptomycin. HL60 (human promyelocytic leukemia cells), SKBR-3 (human breast cancer cells), and Sp2/0-Ag14 (a mouse myeloma cells) cells were obtained from National Infrastructure of Cell Line Resource (China) and cultured in RPMI 1640 medium supplemented with 10% FBS, 50 μg/mL penicillin, and streptomycin. All cells were incubated at 37˚C in a 5% CO 2 humidified atmosphere.
Animal ethics
We obtained the necessary licenses and approvals from the Institutional Animal Care and Use Committee of Peking University (Permit Number: SYXK [Beijing] 2016-0028), who approved all of our animal-related experiments and protocols. BALB/C mice (females weighing 20-25 g) were purchased from Vital River Laboratory Animal Technology (China). Animals were maintained in a sterile environment and feed sterilized food. At the end of the experiments, the animals were euthanized by carbon dioxide.
Research Ethics
We had received ethical approval from the Ethics Committee of Beijing Cancer Hospital. Informed consent was provided by 5 patients (who donated blood samples) and was approved by Institutional Review Board and Beijing Cancer Hospital and signed by 5 patients. All procedures were performed in accordance with relevant guidelines and regulations. Vacutainer tubes containing the anticoagulant ethylene-diaminetetraacetic acid were used to collect blood samples (4 mL from each individual). The samples were placed at room temperature and processed within 24 h.
Glycosylated protein expression, purification, and examination
cDNA encoding human CD45 was amplified by reverse transcriptase-PCR from total RNA extracted from HL60 cells and then cloned into the pMD19-T vector. Using the pMD19-T vector (3721, Takara Biomedical Technology), as the template, the fragment encoding extracellular CD45 was amplified and inserted into the pCDNA3.1 vector (CV003, Sino Biological Inc.) to generate the recombinant vector pCDNA3.1-CD45-his. cDNA encoding the CD45 ectodomain was amplified with the primers: 5 0 -GGAATTGTACCCGCGGGCCCCGCCACCATGCAAAGCCCAACACCTTCCC-3 0 (forward) and 5 0 -GATCTCGGTCGACCGAATTCTCAATGATGATGATGATGATGCTTAGAATTATAAG ATGTTG-3 0 (reverse). The inserted nucleotide sequence was verified by DNA sequencing. The recombinant vector pCDNA3.1-CD45-his was transfected into HEK293T cells using Lipofectamine 2000. The recombinant protein was purified using Ni-NTA agarose (Beijing Biodragon Immunotechnologies, China). The protein purity was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and its concentration was measured using the BCA Assay Kit (Solarbio, China). Finally, 2 mg protein was obtained from 200 mL cell culture supernatants and stored at -20˚C.
For glycosylation analysis, the rhCD45-his protein was reduced for 40 min with 5 mM dithiothreitol in 25 mM NH 4 HCO 3 at room temperature and alkylated for 40 min with 15 mM iodoacetamide in 25 mM NH 4 HCO 3 in the dark. After being washed and dehydrated, the alkylated sample was digested overnight at 37˚C with trypsin (Promega, USA), using a 1: 50 enzyme: substrate ratio. After digestion, the peptide mixtures were extracted with 50% acetonitrile and 0.1% trifluoroacetic acid for 2 h at 37˚C. The peptide sample was dried, dissolved in 10 μL 0.1% formic acid, and subjected to nano liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
For western blot assays, the rhCD45-his protein was reduced with loading buffer and boiled for 5 min. Two micrograms rhCD45-his protein and 2 μg PD-L1-his protein were added to separate lanes. After electrophoresis and blotting, the blots were blocked in PBS containing 5% skim milk and 0.1% Tween-20 (mPBST) at room temperature and then incubated with a primary antibody (mouse anti-his monoclonal antibody) in mPBST overnight at 4˚C. The blots were washed in PBS with 0.1% Tween-20 (PBST) and incubated with an HRP-conjugated goat anti-mouse IgG secondary antibody in mPBST for 1 h at room temperature. The blots were washed again before the bands were detected.
Mice immunization and hybridoma screening
For the first mouse immunization, a 500-μL sample (50 μg rhCD45-his protein dissolved in 250 μL PBS plus 250 μL complete Freund's adjuvant) was subcutaneously injected into each mouse. For the following 2 immunizations, complete Freund's adjuvant was replaced by incomplete Freund's adjuvant. The interval between each immunization was 2 weeks. Enzyme-linked immunosorbent assay (ELISA) and flow cytometry were used to screen for hybridomas that secreted anti-CD45 antibodies. Hybridoma cell lines were established after 2 cycles of sub-cloning. ELISA plates were coated with rhCD45-his protein (1 μg/mL) or betaine homocysteine s-methyltransferase (BHMT)-his protein (1μg/mL) in carbonate buffer and incubated overnight at 4˚C. Then, the plates were blocked with PBS containing 5% milk (mPBS) and incubated for 1 h at 4˚C. The primary antibody consisted of antiserum collected from immunized mice (or the purified CD45 antibody) diluted in mPBS, which was incubated with the ELISA plate for 1 h at 37˚C. After being washed 3 times with PBST, the plates were incubated for 1 h at 37˚C with an HRP-conjugated goat anti-mouse IgG (1: 5000), which was diluted in mPBST. Tetramethylbenzidine was used as substrate to catalyze HRP reactions for 10 min, and 50 μL 2M H 2 SO 4 was used to stop the reaction. The absorbance signal was measured at 450 nm.
mAb characterization
To purify antibodies, ascites were diluted with 10-fold PBS and injected to Protein G affinity chromatography (BDTL0004-5, Beijing Biodragon Immunotechnologie). Alexa647 dye was conjugated to antibody 4D3 by employing a Protein Labeling Kit (A20173, Invitrogen detection technologies).
For surface plasmon resonance (SPR) assays, 2 μL rhCD45 protein (1 μg/μL) was immobilized on a SPR chip (Nanocapture Gold, Plexera LLC, USA) surface modified with a goldlayer and incubated overnight at 4˚C. The chip was blocked in 5% skim milk overnight at 4˚C, washed 3 times in PBS, and dried under a stream of nitrogen. The Alexa647-4D3 and Alexa647-CmAb were diluted in PBST at different concentrations (133, 66.5, 33.3, 16.6, 8.31, and 4.17 nM). SPR analysis was performed with the following cycle: running buffer (PBST, for baseline stabilization); sample (from low to high concentrations) for the binding assays (association phase); running buffer (PBST as dissociation phase, for washing), and 0.5% (v/v) H3PO4 in deionized water (for chip regeneration). After 1 cycle was finished, the next sample was started on the same chip until all samples were completed. Real-time binding signals were recorded and analyzed using the PlexArray HT system (Plexera LLC, USA). The dissociation constant was calculated by fitting the data to association-dissociation curves.
For immunofluorescence analysis, cells were harvested, washed twice with PBS, and fixed with 4% paraformaldehyde. Cells were incubated with 4',6-diamidino-2-phenylindole (DAPI) dye (1:100) for 10 min at room temperature to stain the cell nuclei, after which they were centrifuged for 3 min at 2000 rpm before the supernatant was removed. Five microliters of an Alexa647-labeled antibody (25 μg/mL) was added. After a 1-h incubation at room temperature, the cells were washed in PBS and fluorescently imaged.
For flow cytometry assays, HL60 cells were collected and washed twice in PBS. Cells were incubated with 100uL culture supernatant or 5 μL of Alexa647-labeled anti-CD45 (25 μg/mL) for 1 h at room temperature, while mIgG1 was used as a negative control. In addition, lymphocytes were separated from blood using Lymphocyte Separation Medium (TBD Science, China).
Enumerating CTCs
Two milliliters of peripheral blood from cancer patients was diluted with 5 mL PBS in a 15-mL tube and incubated directly with immunomagnetic beads (Bio-Adembeads Streptavidin 0312, ADEMTECH Inc) modified with a peptide targeting the epithelial cell adhesion molecule (EpCAM) for 1 h at room temperature [9] . EpCAM-positive cells were enriched with a magnetic shelf. Thirty minutes later, the supernatant was removed, and the enriched cells were resuspended in 5 mL PBS. The process of enriching EpCAM-positive cells was repeated 3 times. Two hundred microliters of paraformaldehyde (4%) was added to the tube for 15 min to fix the enriched cells, followed by cell staining with DAPI for 15 min. All cells were treated with 400 μL 0.3 M glycine solution containing 10% normal goat serum for 1 h, and then 20 μL each of Alexa647-labelled anti-CD45 and fluorescein isothiocyanate (FITC)-labeled anti-CK19 antibodies were used to label cells for 1.5 h. Subsequently, the cells were re-suspended in PBS and transferred from the centrifugal tube to a glass slide, on which the cells were fluorescently imaged and identified. All procedures were performed at room temperature.
Results
The overall experimental procedure used in this study is represented schematically in Fig 1. Briefly, a eukaryotic expression plasmid was constructed and transfected into HEK293T cells to produce the glycosylated recombinant human CD45-his protein. After collection and purification, the expressed glycosylated rhCD45-his protein was used to immunize mice. When the antiserum titer was determined to be satisfactory, the mice were sacrificed to retrieve their splenocytes, which were fused with Sp2/0-Ag14 cells to produce hybridomas. The positive hybridoma clones were collected and characterized to generate mAbs, which were further used in immunofluorescent assays to identify leukocytes.
Expression of the glycosylated rhCD45-his protein
CD45 is a type-I transmembrane glycoprotein expressed abundantly on the surfaces of all leukocytes [10] . The native CD45 protein expressed on the surface of leukocytes has extensive post-translational modification in the form of N-linked and O-linked glycosylation [10, 11] . To produce CD45 in heavily glycosylated form, we generated the eukaryotic expression plasmid pCDNA3.1-CD45-his, encoding a 5 0 signal peptide, the extracellular domain of CD45, and a 3 0 6× his tag (Fig 2A) . Accurate construction of the pCDNA3.1-CD45-his plasmid was verified by sequencing (as shown in S1 Fig) . The recombinant vector was transfected into HEK293T cells using Lipofectamine 2000. At 72 h post-transfection, the rhCD45-his protein was purified from the culture supernatant by immobilized affinity chromatography with nickel-nitrilotriacetic acid (Ni-NTA) agarose. As shown in Fig 2B, SDS-PAGE analysis demonstrated that the CD45-his protein was successfully purified. The predicted molecular mass of the CD45 protein is 60 kDa. The protein gel of 6% reduced SDS-PAGE revealed that the molecular mass of rhCD45-his was approximately 140 kDa, suggesting that extensive posttranslational modifications occurred. An anti-his mAb was further used for western blotting to detect CD45-his. As shows in S2 Fig, glycosylated CD45 was successfully expressed in HEK293T cells. As shown in Fig 2C, a reduced SDS-PAGE with PNGase F treatment was used to ensure the existence of sugars. Compared with un-treated protein (lane 1), the PNGase F treatment (lane 2) reduces the molecular weight by eliminating N-glycan.
We then used LC-MS/MS to further investigate the post-translational modifications in detail. 39 glycopeptides were detected on 12 amino acids (as shown in S3 Fig) , hinting that the same amino acid was modified by various glycans.
Mice immunization and hybridoma screening
After acquiring a sufficient amount of heavily glycosylated rhCD45-his protein, 5 mice were immunized 3 times at 14-day intervals. For each immunization, 500 μL (1 μg/μL) rhCD45-his protein was injected per mouse. Seven days after the second immunization, the antiserum titers were determined by indirect ELISA. As shown in Fig 3A, the antibody titers of all mice were more than 1: 32,000, which was high enough for hybridoma preparation and screening [12] . Using normal mouse serum as the negative control and PBS as the blank control, we employed indirect ELISA to investigate the reaction between the rhCD45-his protein and supernatant from each well. Supernatants from 25 wells exhibited reactions with the rhCD45-his protein (as shown in S4 Fig) . Considering that his-tag could also induce immune responses, we used the irrelevant his-tagged protein, BHMT-his [13] , to perform another Although the rhCD45-his protein expressed in eukaryotic cells was glycosylated, its spatial conformation could be different than that of the native protein expressed on leukocyte membranes. Thus, we performed flow cytometry to investigate the reaction between the antibodies in the 25 screened supernatants and HL60 acute promyelocytic leukemia cells, which express glycosylated CD45 on the cell membrane. Compared with mouse IgG, which was used as a negative control, antibodies in 7 supernatants showed clear binding to HL60 cells (Fig 3B) . After performing routine sub-cloning twice to exclude unstable hybridomas, we finally obtained 4 positive hybridomas. Table 1 summarizes several key parameters of the hybridoma-screening procedures. Starting from the first mouse immunization, the entire immunization and hybridoma-screening process required only 2 months to acquire 4 positive hybridomas. Only 1 cell fusion and 2 cycles of sub-cloning were performed. In contrast, in previous studies [4] employing peptides or prokaryotic protein as the antigen, 2 or more cell fusions and hybridoma screens were performed. For most laboratories conducting biological research, efficient time and labor management are key factors influencing the decision whether to generate specific mAbs in house. ) and added to the ELISA plate. An HRP-conjugated goat antimouse IgG was used as the secondary antibody. The cutoff value was set as 2.1 times the control value. Data are presented as the mean ± SD of measurements derived from 2 independent assays. (B) Flow cytometry was performed to determine the binding between HL60 cells and antibodies in the hybridoma supernatants. The ratios of cell numbers were normalized to their maximum values.
https://doi.org/10.1371/journal.pone.0192506.g003 The purpose of producing an anti-CD45 mAb was to immunofluorescently detect glycosylated CD45 on leukocyte membranes. Thus, we fluorescently labeled mAb 4D3 with the fluorescent dye, Alexa647, and the resulting fluorescent labeled mAb was designated Alexa647-4D3. For comparison, we also purchased a commercial anti-CD45 mAb labeled with Alexa647, which was named as Alexa647-CmAb. To quantitatively investigate the binding affinity between Alexa647-4D3 and the glycosylated CD45 protein, we performed SPR assays to calculate the KD, which is widely accepted when characterizing antibody-antigen binding affinities [14] . Compared with Alexa647-CmAb (Fig 5C) , Alexa647-4D3 (Fig 5A) had a lower KD. However, the calculated data exhibited considerable errors. Therefore, it was considered that Alexa647-4D3 had similar affinity with Alexa647-CmAb. To further evaluate the binding between mAbs and native glycosylated CD45 protein on cell surface, we performed immunofluorescence assays with HL60 cells (which express CD45 on the cell membrane) and SKBR3 cells (which are CD45-negative). By directly counting the number of immunofluorescently labeled HL60 cells, it was found that Alexa647-4D3 and Alexa647-CmAb showed similar performance (Fig 4B) . Apart from the affinity, the specificity was also evaluated by performing immunofluorescence assays with the HL60 and SKBR3 cells. Both Alexa647-4D3 and Alexa647-CmAb bound to HL60 cells, but not SKBR3 cells ( S9 Fig). 
Clinical application of identifying CTCs
Enumerating CTCs in the blood has been demonstrated to be helpful for selecting cancer treatment [15] . Although multiple methods have proven effective in isolating CTC-like cells, definitive identification of CTCs still relies on immunofluorescent recognizing specific proteins on the cell membrane. For instance, CK19, a cytokeratin belonging to the type I group, was used to identify breast cancer cells [16, 17] whereas CD45 was used to exclude lymphocyte. We first isolated lymphocytes from patient blood samples to investigate binding between the mAbs and CD45 on lymphocyte membranes. As shown in Fig 4C, our flow cytometry results demonstrated that Alexa647-4D3 and Alexa647-CmAb performed similarly. To ensure that the Alexa647-4D3 binds all types of lymphocytes, we employed diverse cell surface markers to differentiate lymphocyte subsets, while evaluating Alexa647-4D3 binding to each subset. The results (S10 Fig) demonstrated that Alexa647-4D3 recognized all lymphocyte subsets, including T cells, B cells, and NK cells. To enable the clinical application of Alexa647-4D3, we tested mAbs with blood samples from 4 female breast cancer patients. Patient 1 was at stage 2a and receiving second-line chemotherapy; patient 2 was at stage 3b and receiving fourth-line chemotherapy; patient 3 was at stage 2b and receiving endocrine therapy; and patient 4 was at stage 2a and receiving third-line chemotherapy. As shown in Fig 6 and Table 2 , Alexa647-4D3 and Alexa647-CmAb performed similarly.
Overall, Alexa647-4D3 and Alexa647-CmAb performed similarly in recognizing lymphocytes and CTC enumeration. However, before selecting Alexa647-CmAb, 2 commercial anti-CD45 mAbs which were purchased from Sino Biological (10086-MM05-F-25) and Abbiotec (251081) failed at CTC enumeration because of their weak binding with native CD45 on lymphocyte membranes (S11 Fig). 
Discussion and conclusions
A stable supply of high-quality mAbs is crucial for conducting most protein-related studies in laboratories engaged in biological research. Commercial mAbs are normally considered easy to access and helpful for saving time and labor costs (versus producing mAbs in-house). However, for unusual or heavily glycosylated proteins, purchasing commercial mAbs may not be a good choice. First, there could be a long period before shipping orders, considering that providers need to prepare antibodies from the initial immunization stage. Second and more importantly, it is likely that the specificity and affinity of commercial mAbs are uncertain, especially for specifically glycosylated proteins. For instance, fluorescent staining of heavily glycosylated CD45 on leukocytes has become the most common method for differentiating Producing CD45 mAbs for identifying CTC CTCs from leukocytes. The method requires large quantities of mAbs with satisfactory affinity and high specificity, as the number of CTCs are quite low (usually <100 in 2 mL blood), compared with the number of leukocyte (10 6 in 2 mL blood). Using our own experience as an example, we spent >8 months on testing 3 kinds of antibodies from 3 different manufacturers before obtaining an acceptable mAb. However, the next batch of mAbs failed to meet our requirements. While encountering such issues, tend to simply try other antibodies or query related databases, for instance, www.antibodypedia.com. The potential impact of glycosylation For CTC enumeration, EpCAM-positive cells were first isolated from patient blood samples, after which they were immunofluorescently identified. DAPI (blue) was used to stain the cell nucleus. Alexa-647-labeled anti-CD45 antibodies (red) were used to stain the leukocyte marker CD45. FITC-labeled anti-CK19 antibodies (green) were used to stain CK19, which is widely accepted as a marker of breast cancer CTCs. Therefore, CTCs (A) exhibited a status of DAPI+/CD45-/CK19+, which were colored blue and green, but not red. Typical leukocytes (B) were DAPI+/CD45+/CK19-and colored blue and red, but not green. Scale bar: 5 μm.
https://doi.org/10.1371/journal.pone.0192506.g006 on antibody recognition has not been comprehensively investigated. Still, some studies [4] inferred that the mismatch between unglycosylated antigen and glycosylated target protein might cause the fluctuations in antibody binding. The purpose of this study was to provide a reference for biological laboratories demanding appropriate mAbs and facing a similar dilemma: i.e., what kind of antigen should be used (eukaryotically expressed protein, prokaryotically expressed protein, or peptides). Although only the heavily glycosylated CD45 protein was used, this study still provides direct evidence that using a eukaryotically expressed protein as the antigen was efficient in producing mAbs targeting a heavily glycosylated protein. Efforts in plasmid construction and preparing the eukaryotic protein paid off in terms of lowering the time requirements and enhancing the binding affinity. Author Contributions
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